These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 34849601

  • 1. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
    Nurmohamed NS, Ditmarsch M, Kastelein JJP.
    Cardiovasc Res; 2022 Nov 10; 118(14):2919-2931. PubMed ID: 34849601
    [Abstract] [Full Text] [Related]

  • 2. Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels.
    Nelson AJ, Sniderman AD, Ditmarsch M, Dicklin MR, Nicholls SJ, Davidson MH, Kastelein JJP.
    Int J Mol Sci; 2022 Aug 20; 23(16):. PubMed ID: 36012684
    [Abstract] [Full Text] [Related]

  • 3. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
    Johns DG, Duffy J, Fisher T, Hubbard BK, Forrest MJ.
    Drugs; 2012 Mar 05; 72(4):491-507. PubMed ID: 22356288
    [Abstract] [Full Text] [Related]

  • 4. Structure-based mechanism and inhibition of cholesteryl ester transfer protein.
    Xue H, Zhang M, Liu J, Wang J, Ren G.
    Curr Atheroscler Rep; 2023 Apr 05; 25(4):155-166. PubMed ID: 36881278
    [Abstract] [Full Text] [Related]

  • 5. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
    Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, Packard CJ, Laufs U, Brook RD, Oliver-Williams C, Butterworth AS, Danesh J, Smith GD, Catapano AL, Sabatine MS.
    JAMA; 2017 Sep 12; 318(10):947-956. PubMed ID: 28846118
    [Abstract] [Full Text] [Related]

  • 6. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H.
    Vasc Health Risk Manag; 2012 Sep 12; 8():323-31. PubMed ID: 22661899
    [Abstract] [Full Text] [Related]

  • 7. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Mohammadpour AH, Akhlaghi F.
    Clin Pharmacokinet; 2013 Aug 12; 52(8):615-26. PubMed ID: 23658137
    [Abstract] [Full Text] [Related]

  • 8. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
    Schaefer EJ.
    Curr Opin Lipidol; 2013 Jun 12; 24(3):259-64. PubMed ID: 23652567
    [Abstract] [Full Text] [Related]

  • 9. Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments.
    Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M, Davidson MH.
    Curr Atheroscler Rep; 2024 Feb 12; 26(2):35-44. PubMed ID: 38133847
    [Abstract] [Full Text] [Related]

  • 10. Cholesteryl ester transfer protein inhibitors in precision medicine.
    Su X, Li G, Deng Y, Chang D.
    Clin Chim Acta; 2020 Nov 12; 510():733-740. PubMed ID: 32941836
    [Abstract] [Full Text] [Related]

  • 11. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week.
    Armitage J, Holmes MV, Preiss D.
    J Am Coll Cardiol; 2019 Feb 05; 73(4):477-487. PubMed ID: 30704580
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia.
    Poliakova T, Wellington CL.
    Mol Neurodegener; 2023 Nov 16; 18(1):86. PubMed ID: 37974180
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial.
    Ballantyne CM, Ditmarsch M, Kastelein JJ, Nelson AJ, Kling D, Hsieh A, Curcio DL, Maki KC, Davidson MH, Nicholls SJ.
    J Clin Lipidol; 2023 Nov 16; 17(4):491-503. PubMed ID: 37277261
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease.
    Mehta N, Dangas K, Ditmarsch M, Rensen PCN, Dicklin MR, Kastelein JJP.
    Pharmacol Res; 2023 Nov 16; 197():106972. PubMed ID: 37898443
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Present therapeutic role of cholesteryl ester transfer protein inhibitors.
    Ferri N, Corsini A, Sirtori CR, Ruscica M.
    Pharmacol Res; 2018 Feb 16; 128():29-41. PubMed ID: 29287689
    [Abstract] [Full Text] [Related]

  • 20. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
    van der Tuin SJ, Kühnast S, Berbée JF, Verschuren L, Pieterman EJ, Havekes LM, van der Hoorn JW, Rensen PC, Jukema JW, Princen HM, Willems van Dijk K, Wang Y.
    J Lipid Res; 2015 Nov 16; 56(11):2085-93. PubMed ID: 26342106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.